Compass Therapeutics’ (CMPX) Buy Rating Reiterated at Guggenheim

Guggenheim reiterated their buy rating on shares of Compass Therapeutics (NASDAQ:CMPX) in a report published on Wednesday morning,Benzinga reports. They currently have a $12.00 target price on the stock.

Several other analysts have also recently weighed in on the company. HC Wainwright reissued a “buy” rating and set a $10.00 price objective on shares of Compass Therapeutics in a report on Wednesday, January 8th. Jefferies Financial Group boosted their price target on shares of Compass Therapeutics from $7.00 to $8.00 and gave the stock a “buy” rating in a research note on Monday, February 10th. D. Boral Capital reaffirmed a “buy” rating and issued a $32.00 price objective on shares of Compass Therapeutics in a research note on Tuesday. Wedbush reissued an “outperform” rating and issued a $8.00 price target on shares of Compass Therapeutics in a research note on Tuesday. Finally, Piper Sandler initiated coverage on Compass Therapeutics in a research report on Wednesday, February 19th. They issued an “overweight” rating and a $12.00 price target on the stock. Eight analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $13.38.

Compass Therapeutics Stock Down 9.0 %

Shares of NASDAQ:CMPX opened at $1.46 on Wednesday. Compass Therapeutics has a 12 month low of $0.77 and a 12 month high of $4.08. The firm has a market cap of $201.89 million, a P/E ratio of -3.95 and a beta of 1.19. The company’s 50-day moving average price is $2.76 and its two-hundred day moving average price is $2.10.

Compass Therapeutics (NASDAQ:CMPX) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.01). As a group, equities analysts predict that Compass Therapeutics will post -0.36 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Compass Therapeutics

Several institutional investors have recently modified their holdings of the business. Tower Research Capital LLC TRC raised its holdings in shares of Compass Therapeutics by 298.0% during the fourth quarter. Tower Research Capital LLC TRC now owns 17,251 shares of the company’s stock worth $25,000 after acquiring an additional 12,917 shares during the period. Independent Advisor Alliance bought a new stake in shares of Compass Therapeutics in the fourth quarter valued at about $26,000. BNP Paribas Financial Markets bought a new stake in shares of Compass Therapeutics in the fourth quarter valued at about $27,000. Intech Investment Management LLC acquired a new position in shares of Compass Therapeutics during the third quarter worth about $30,000. Finally, Mariner LLC bought a new position in shares of Compass Therapeutics during the fourth quarter worth about $30,000. Institutional investors own 68.43% of the company’s stock.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.